[Treatment options for marginal zone lymphoma].

Marginal zone lymphoma (MZL) is a group of indolent B-cell lymphomas with high biological and clinical heterogeneity, including mucosa-associated lymphoid tissue, nodal, and splenic MZL. Despite diverse first-line treatment options, significant differences exist between guidelines and clinical practices, lacking a unified and standardized treatment pathway.Therefore, this article elaborates on the assessment of treatment indications of MZL, the initial therapies for different MZL subtypes, and summarizes the treatment for relapsed/refractory MZL, the selection of maintenance therapy, and management of treatment-related complications, aiming to offer evidence-based guidance and individualized therapeutic decision-making in clinical practice.